B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $3
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $5 to $3.
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $5 to $3.